Commercial development of cell-based therapeutics: Strategic considerations along the drug to tissue spectrum

Regenerative Medicine

Volumn 4, Issue 4, 2009, Pages 601-611

  Parenteau, Nancy L ^a  

^a Parenteau BioConsultants   (United States)

Author keywords

Allogeneic; Autologous; Biologics; Cardiac repair; Cell based; Cell therapy; Commercialization; Epidermal cell; Progenitor cells; R D; Skin construct stem cells

Indexed keywords

ARTICLE; BIOTECHNOLOGY; CELL DIFFERENTIATION; CELL FUNCTION; CELL REGENERATION; CELL THERAPY; COMMERCIAL PHENOMENA; EMBRYONIC STEM CELL; HEART INFARCTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; SAFETY; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; BIOLOGICAL THERAPY; CYTOLOGY; EPIDERMIS; METHODOLOGY; REGENERATIVE MEDICINE; REVIEW; STEM CELL; TISSUE ENGINEERING;

COMMERCE; EPIDERMIS; REGENERATIVE MEDICINE; SAFETY; STEM CELLS; TISSUE ENGINEERING; TISSUE THERAPY;

EID: 70349759090     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/rme.09.29     Document Type: Article

References (74)

1. Kinnaird T, Stabile E, Burnett MS et al.: Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 109, 1543-1549 (2004).
2. Nakagami H, Maeda K, Morishita R et al.: Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells. Arterioscler. Thromb. Vasc. Biol. 25, 2542-2547 (2005).
3. Capone C, Frigerio S, Fumagalli S et al.: Neurosphere-derived cells exert a neuroprotective action by changing the ischemic microenvironment. PLoS ONE 2, e373 (2007).
4. Aharonowiz M, Einstein O, Fainstein N, Lassmann H, Reubinoff B, Ben-Hur T: Neuroprotective effect of transplanted human embryonic stem cell-derived neural precursors in an animal model of multiple sclerosis. PLoS ONE 3, e3145 (2008).
5. Ohtaki H, Ylostalo JH, Foraker JE et al.: Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses. Proc. Natl Acad. Sci. USA 105, 14638-14643 (2008).
6. + cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J. Clin. Invest. 116, 1865-1877 (2006).
7. Caplan AI: Review: mesenchymal stem cells: cell-based reconstructive therapy in orthopedics. Tissue Eng. 11, 1198-1211 (2005).
8. Goldman SA, Windrem MS: Cell replacement therapy in neurological disease. Philos. Trans. R. Soc. Lond. B Biol. Sci. 361, 1463-1475 (2006).
9. Hu X, Wang J, Chen J et al.: Optimal temporal delivery of bone marrow mesenchymal stem cells in rats with myocardial infarction. Eur. J. Cardiothorac. Surg. 31, 438-443 (2007).
10. Eming SA, Krieg T, Davidson JM: Inflammation in wound repair: molecular and cellular mechanisms. J. Invest. Dermatol. 127, 514-525 (2007).
11. Pluchino S, Muzio L, Imitola J et al.: Persistent inflammation alters the function of the endogenous brain stem cell compartment. Brain 131(10), 2564-2578 (2008).
12. Kopp HG, Hooper AT, Broekman MJ et al.: Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization. J. Clin. Invest. 116, 3277-3291 (2006).
13. Gallico GG, 3rd, O'Connor NE, Compton CC, Kehinde O, Green H: Permanent coverage of large burn wounds with autologous cultured human epithelium. N. Engl. J. Med. 311, 448-451 (1984).
14. Phillips TJ, Gilchrest BA: Cultured allogenic keratinocyte grafts in the management of wound healing: prognostic factors. J. Dermatol. Surg. Oncol. 15, 1169-1176 (1989).
15. Phillips TJ, Gilchrest BA: Cultured epidermal grafts in the treatment of leg ulcers. Adv. Dermatol. 5, 33-48; discussion 49 (1990).
16. Hardin-Young J, Parenteau NL: Progenitor cell properties and the engineering of tissues. Curr. Neurovasc. Res. 1, 241-249 (2004).
17. Parenteau N, Sabolinski M, Prosky S et al.: Biological and physical factors influencing the successful engraftment of a cultured human skin substitute. Biotechnol. Bioeng. 52, 3-14 (1996).
18. Phillips TJ, Manzoor J, Rojas A et al.: The longevity of a bilayered skin substitute after application to venous ulcers. Arch. Dermatol. 138, 1079-1081 (2002).
19. Sabolinski ML, Alvarez O, Auletta M, Mulder G, Parenteau NL: Cultured skin as a 'smart material' for healing wounds: experience in venous ulcers. Biomaterials 17, 311-320 (1996).
20. Falanga V, Isaacs C, Paquette D et al.: Wounding of bioengineered skin: cellular and molecular aspects after injury. J. Invest. Dermatol. 119, 653-660 (2002).
21. Taylor DA, Zenovich AG: Cardiovascular cell therapy and endogenous repair. Diabetes Obes. Metab. 10(Suppl. 4), 5-15 (2008).
22. Haider H, Tan AC, Aziz S, Chachques JC, Sim EK: Myoblast transplantation for cardiac repair: a clinical perspective. Mol. Ther. 9, 14-23 (2004).
23. Burchfield JS, Dimmeler S: Role of paracrine factors in stem and progenitor cell mediated cardiac repair and tissue fibrosis. Fibrogenesis Tissue Repair 1, 4 (2008).
24. Fukuchi Y, Nakajima H, Sugiyama D, Hirose I, Kitamura T, Tsuji K: Human placenta-derived cells have mesenchymal stem/progenitor cell potential. Stem Cells 22, 649-658 (2004).
25. Zuk PA, Zhu M, Ashjian P et al.: Human adipose tissue is a source of multipotent stem cells. Mol. Biol. Cell 13, 4279-4295 (2002).
26. Tsai MS, Lee JL, Chang YJ, Hwang SM: Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. Hum. Reprod. 19, 1450-1456 (2004).
27. Tse HF, Thambar S, Kwong YL et al.: Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial). Eur. Heart J. 28, 2998-3005 (2007).
28. Nauta AJ, Fibbe WE: Immunomodulatory properties of mesenchymal stromal cells. Blood 110, 3499-3506 (2007).
29. van den Bos EJ, van der Giessen WJ, Duncker DJ: Cell transplantation for cardiac regeneration: where do we stand? Neth. Heart J. 16, 88-95 (2008).
30. Alhadlaq A, Mao JJ: Mesenchymal stem cells: isolation and therapeutics. Stem Cells Dev. 13, 436-448 (2004).
31. Xu W, Zhang X, Qian H et al.: Mesenchymal stem cells from adult human bone marrow differentiate into a cardiomyocyte phenotype in vitro. Exp. Biol. Med. (Maywood) 229, 623-631 (2004).
32. Rota M, Kajstura J, Hosoda T et al.: Bone marrow cells adopt the cardiomyogenic fate in vivo. Proc. Natl Acad. Sci. USA 104, 17783-17788 (2007).
33. Cho HJ, Lee N, Lee JY et al.: Role of host tissues for sustained humoral effects after endothelial progenitor cell transplantation into the ischemic heart. J. Exp. Med. 204, 3257-3269 (2007).
34. Giordano A, Galderisi U, Marino IR: From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J. Cell. Physiol. 211, 27-35 (2007).
35. Placzek MR, Chung IM, Macedo HM et al.: Stem cell bioprocessing: fundamentals and principles. J. R. Soc. Interface 6, 209-232 (2009).
36. Condic ML, Rao M: Regulatory issues for personalized pluripotent cells. Stem Cells 26, 2753-2758 (2008).
37. Johnson EW, Meunier SF, Roy CJ, Parenteau NL: Serial cultivation of normal human keratinocytes: a defined system for studying the regulation of growth and differentiation. In Vitro Cell Dev. Biol. 28A, 429-435 (1992).
38. Djukic M, Mildner A, Schmidt H et al.: Circulating monocytes engraft in the brain, differentiate into microglia and contribute to the pathology following meningitis in mice. Brain 129, 2394-2403 (2006).
39. Zeng L, Hu Q, Wang X et al.: Bioenergetic and functional consequences of bone marrow-derived multipotent progenitor cell transplantation in hearts with postinfarction left ventricular remodeling. Circulation 115, 1866-1875 (2007).
40. Bearzi C, Rota M, Hosoda T et al.: Human cardiac stem cells. Proc. Natl Acad. Sci. USA 104, 14068-14073 (2007).
41. Schuster MD, Kocher AA, Seki T et al.: Myocardial neovascularization by bone marrow angioblasts results in cardiomyocyte regeneration. Am. J. Physiol. Heart Circ. Physiol. 287, H525-H532 (2004).
42. Urbich C, Dimmeler S: Endothelial progenitor cells: characterization and role in vascular biology. Circ. Res. 95, 343-353 (2004).
43. Taupin P: Adult neurogenesis, neuroinflammation and therapeutic potential of adult neural stem cells. Int. J. Med. Sci. 5, 127-132 (2008).
44. Compton CC, Hickerson W, Nadire K, Press W: Acceleration of skin regeneration from cultured epithelial autografts by transplantation to homograft dermis. J. Burn Care Rehabil. 14, 653-662 (1993).
45. Rehman J, Traktuev D, Li J et al.: Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 109, 1292-1298 (2004).
46. Rafii S, Lyden D: Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat. Med. 9, 702-712 (2003).
47. Ricci-Vitiani L, Lombardi DG, Signore M et al.: Human neural progenitor cells display limited cytotoxicity and increased oligodendrogenesis during inflammation. Cell Death Differ. 14, 876-878 (2007).
48. Ries C, Egea V, Karow M, Kolb H, Jochum M, Neth P: MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines. Blood 109, 4055-4063 (2007).
49. Widera D, Kaus A, Kaltschmidt C, Kaltschmidt B: Neural stem cells, inflammation and NF-κB: basic principle of maintenance and repair or origin of brain tumours? J. Cell Mol. Med. 12, 459-470 (2008).
50. Coyne TM, Marcus AJ, Woodbury D, Black IB: Marrow stromal cells transplanted to the adult brain are rejected by an inflammatory response and transfer donor labels to host neurons and glia. Stem Cells 24, 2483-2492 (2006).
51. Qin JZ, Bacon P, Chaturvedi V, Nickoloff BJ: Role of NF-κB activity in apoptotic response of keratinocytes mediated by interferon-γ, tumor necrosis factor-α, and tumor-necrosis-factor-related apoptosis-inducing ligand. J. Invest. Dermatol. 117, 898-907 (2001).
52. Banno T, Gazel A, Blumenberg M: Effects of tumor necrosis factor-α (TNF-α) in epidermal keratinocytes revealed using global transcriptional profiling. J. Biol. Chem. 279, 32633-32642 (2004).
53. Ortiz LA, Dutreil M, Fattman C et al.: Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc. Natl Acad. Sci. USA 104, 11002-11007 (2007).
54. He W, Li AG, Wang D et al.: Overexpression of Smad7 results in severe pathological alterations in multiple epithelial tissues. EMBO J. 21, 2580-2590 (2002).
55. Dai C, Yang J, Liu Y: Transforming growth factor-β1 potentiates renal tubular epithelial cell death by a mechanism independent of Smad signaling. J. Biol. Chem. 278, 12537-12545 (2003).
56. Leask A, Abraham DJ: TGF-β signaling and the fibrotic response. FASEB J. 18, 816-827 (2004).
57. Waymack P, Duff RG, Sabolinski M: The effect of a tissue engineered bilayered living skin analog, over meshed split-thickness autografts on the healing of excised burn wounds. The Apligraf Burn Study Group. Burns 26, 609-619 (2000).
58. Yang XF: Immunology of stem cells and cancer stem cells. Cell Mol. Immunol. 4, 161-171 (2007).
59. Ryan JM, Barry FP, Murphy JM, Mahon BP: Mesenchymal stem cells avoid allogeneic rejection. J. Inflamm. (Lond.) 2, 8 (2005).
60. + and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation 110, 1209-1212 (2004).
61. Blancke F, Claeys MJ, Jorens P et al.: Systemic inflammation and reperfusion injury in patients with acute myocardial infarction. Mediators Inflamm. 385-389 (2005).
62. Dean RG, Balding LC, Candido R et al.: Connective tissue growth factor and cardiac fibrosis after myocardial infarction. J. Histochem. Cytochem. 53, 1245-1256 (2005).
63. Frangogiannis NG, Ren G, Dewald O et al.: Critical role of endogenous thrombospondin-1 in preventing expansion of healing myocardial infarcts. Circulation 111, 2935-2942 (2005).
64. Hardin-Young J, Parenteau NL: Progenitor cell properties and the engineering of tissues. Curr. Neurovasc. Res. 1, 241-249 (2004).
65. Parenteau NL, Rosenberg L, Hardin-Young J: The engineering of tissues using progenitor cells. Curr. Top. Dev. Biol. 64, 101-139 (2004).
66. Shefer G, Wleklinski-Lee M, Yablonka-Reuveni Z: Skeletal muscle satellite cells can spontaneously enter an alternative mesenchymal pathway. J. Cell. Sci. 117, 5393-5404 (2004).
67. Armaka M, Apostolaki M, Jacques P, Kontoyiannis DL, Elewaut D, Kollias G: Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J. Exp. Med. 205, 331-337 (2008).
68. Bellini A, Mattoli S: The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab. Invest. 87, 858-870 (2007).
69. Tolar J, Nauta AJ, Osborn MJ et al.: Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 25, 371-379 (2007).
70. Park KS, Lee YS, Kang KS: In vitro neuronal and osteogenic differentiation of mesenchymal stem cells from human umbilical cord blood. J. Vet. Sci. 7, 343-348 (2006).
71. Takashima S, Ise H, Zhao P, Akaike T, Nikaido T: Human amniotic epithelial cells possess hepatocyte-like characteristics and functions. Cell Struct. Funct. 29, 73-84 (2004).
72. Yang L, Li S, Hatch H et al.: In vitro trans-differentiation of adult hepatic stem cells into pancreatic endocrine hormone-producing cells. Proc. Natl Acad. Sci. USA 99, 8078-8083 (2002).
73. Blow N: Stem cells: in search of common ground. Nature 451, 855-858 (2008).
74. Parenteau N: Skin: the first tissue-engineered products. Sci. Am. 280, 83-84 (1999).